Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

AtriCure, Inc. develops, manufactures, and sells surgical devices to create precise lesions in soft tissues. The Company offers bipolar ablation systems uses by cardiothoracic surgeons as a standard treatment alternative to create lesions in heart tissue to block the abnormal electrical impulses that cause atrial fibrillation. AtriCure serves customers worldwide.
Website: atricure.com



Growth: Good revenue growth rate 21.6%, there is slowdown compared to average historical growth rates 25.5%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -4.0%. On average the margin is decreasing steadily. Gross margin is high, +74.2%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 1.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 2.3% higher than minimum and 73.4% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.5x by EV / Sales multiple , the company can be 1.8% undervalued

Insiders: For the last 3 months insiders sold company shares on $0.5 mln (-0.029% of cap.)

Key Financials (Download financials)

Ticker: ATRC
Share price, USD:  (+2.3%)23.14
year average price 40.18  


year start price 43.99 2023-04-28

max close price 57.73 2023-07-26

min close price 22.61 2024-04-25

current price 23.14 2024-04-26
Common stocks: 45 912 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  21.6%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  25.5%
Historical growth of EBITDA:  ---
EV / Sales: 2.5x
Margin (EBITDA LTM / Revenue): -4.0%
Fundamental value created in LTM:
Market Cap ($m): 1 062
Net Debt ($m): -63
EV (Enterprise Value): 999
Price to Book: 2.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-19Zacks Investment Research

AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management

2024-02-15Seeking Alpha

AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript

2024-02-15Zacks Investment Research

Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings

2024-02-15Zacks Investment Research

AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates

2023-11-10Seeking Alpha

AtriCure: Appeal Lures For This Cure

2023-11-06Zacks Investment Research

All You Need to Know About AtriCure (ATRC) Rating Upgrade to Buy

2023-11-01Seeking Alpha

AtriCure, Inc. (ATRC) Q3 2023 Earnings Call Transcript

2023-11-01Zacks Investment Research

AtriCure (ATRC) Reports Q3 Earnings: What Key Metrics Have to Say

2023-07-25Zacks Investment Research

AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

2023-07-25Seeking Alpha

AtriCure, Inc. (ATRC) Q2 2023 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ATRC ATRC ATRC ATRC ATRC ATRC
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-16 2023-11-02 2023-07-26 2023-05-03 2023-02-22 2022-11-02
acceptedDate 2024-02-16 14:10:25 2023-11-02 12:17:44 2023-07-26 13:42:17 2023-05-03 12:32:32 2023-02-22 13:07:54 2022-11-02 13:56:39
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 107M 98M 101M 93M 88M 83M
costOfRevenue 27M 24M 24M 24M 23M 22M
grossProfit 79M 74M 77M 70M 65M 62M
grossProfitRatio 0.742 0.752 0.764 0.745 0.740 0.741
researchAndDevelopmentExpenses 21M 20M 17M 15M 14M 15M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 67M 62M 64M 60M 56M 57M
otherExpenses 9000.000 -919 000 -881 000 -616 000 0 0
operatingExpenses 88M 82M 81M 75M 69M 72M
costAndExpenses 115M 106M 105M 99M 92M 94M
interestIncome 1M 915 000 961 000 875 000 1M 370 000
interestExpense 2M -2M -2M -2M 2M 1M
depreciationAndAmortization 4M 4M 4M 3M 0 3M
ebitda -4M -8M -4M -6M -4M -8M
ebitdaratio -0.042 -0.082 -0.041 -0.062 -0.047 -0.095
operatingIncome -9M -8M -4M -6M -4M -11M
operatingIncomeRatio -0.081 -0.082 -0.041 -0.062 -0.047 -0.129
totalOtherIncomeExpensesNet -748 000 -919 000 -881 000 -616 000 87 000 -2M
incomeBeforeTax -9M -9M -5M -6M -4M -12M
incomeBeforeTaxRatio -0.088 -0.092 -0.050 -0.068 -0.046 -0.147
incomeTaxExpense 373 000 47 000 93 000 78 000 121 000 46 000
netIncome -10M -9M -5M -6M -4M -12M
netIncomeRatio -0.092 -0.092 -0.051 -0.069 -0.047 -0.147
eps -0.210 -0.200 -0.110 -0.140 -0.091 -0.270
epsdiluted -0.210 -0.200 -0.110 -0.140 -0.091 -0.270
weightedAverageShsOut 46M 46M 46M 46M 46M 46M
weightedAverageShsOutDil 46M 46M 46M 46M 46M 46M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ATRC ATRC ATRC ATRC ATRC ATRC
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-16 2023-11-02 2023-07-26 2023-05-03 2023-02-22 2022-11-02
acceptedDate 2024-02-16 14:10:25 2023-11-02 12:17:44 2023-07-26 13:42:17 2023-05-03 12:32:32 2023-02-22 13:07:54 2022-11-02 13:56:39
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 84M 81M 67M 77M 58M 49M
shortTermInvestments 53M 52M 60M 59M 63M 74M
cashAndShortTermInvestments 137M 133M 127M 136M 121M 123M
netReceivables 53M 52M 48M 46M 43M 41M
inventory 68M 62M 55M 49M 46M 44M
otherCurrentAssets 9M 6M 7M 8M 5M 4M
totalCurrentAssets 266M 253M 238M 238M 215M 212M
propertyPlantEquipmentNet 47M 45M 45M 44M 43M 43M
goodwill 235M 235M 235M 235M 235M 235M
intangibleAssets 64M 66M 67M 39M 39M 40M
goodwillAndIntangibleAssets 299M 300M 302M 273M 274M 275M
longTermInvestments 0 0 8M 26M 52M 51M
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 2M 2M 2M 2M 2M 829 000
totalNonCurrentAssets 348M 348M 356M 345M 370M 370M
otherAssets 1.000 0 0 0 0 0
totalAssets 614M 600M 594M 583M 585M 582M
accountPayables 27M 25M 24M 24M 20M 24M
shortTermDebt 3M 21M 16M 11M 5M 2M
taxPayables 0 0 0 0 0 2M
deferredRevenue 0 0 0 0 0 0
otherCurrentLiabilities 45M 37M 32M 28M 33M 31M
totalCurrentLiabilities 75M 83M 71M 62M 58M 58M
longTermDebt 61M 54M 59M 65M 69M 73M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 13M 1M 1M 1M 1M 48M
totalNonCurrentLiabilities 73M 55M 60M 66M 70M 74M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 11M 12M 12M 13M 12M 15M
totalLiabilities 148M 137M 132M 128M 129M 132M
preferredStock 0 0 0 0 0 0
commonStock 48 000 47 000 47 000 47 000 47 000 46 000
retainedEarnings -357M -347M -338M -333M -327M -322M
accumulatedOtherComprehensiveIncomeLoss -993 000 -2M -3M -3M -4M -5M
othertotalStockholdersEquity 824M 812M 803M 791M 787M 778M
totalStockholdersEquity 466M 463M 462M 455M 457M 450M
totalEquity 466M 463M 462M 455M 457M 450M
totalLiabilitiesAndStockholdersEquity 614M 600M 594M 583M 585M 582M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 614M 600M 594M 583M 585M 582M
totalInvestments 53M 52M 67M 84M 115M 125M
totalDebt 74M 74M 75M 75M 69M 75M
netDebt -10M -6M 8M -2M 11M 26M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ATRC ATRC ATRC ATRC ATRC ATRC
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-16 2023-11-02 2023-07-26 2023-05-03 2023-02-22 2022-11-02
acceptedDate 2024-02-16 14:10:25 2023-11-02 12:17:44 2023-07-26 13:42:17 2023-05-03 12:32:32 2023-02-22 13:07:54 2022-11-02 13:56:39
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -10M -9M -5M -6M -4M -12M
depreciationAndAmortization 4M 4M 4M 3M 3M 3M
deferredIncomeTax -22M 167 000 125 000 0 0 0
stockBasedCompensation 9M 9M 9M 9M 7M 7M
changeInWorkingCapital -496 000 -3M -5M -10M -6M -696 000
accountsReceivables -932 000 -3M -3M -3M -4000.000 -228 000
inventory -6M -7M -7M -3M -2M -3M
accountsPayables 2M 1M -121 000 3M -3M 1M
otherWorkingCapital 4M 6M 4M -7M -914 000 1M
otherNonCashItems 23M 606 000 449 000 450 000 -389 000 1M
netCashProvidedByOperatingActivities 4M 2M 3M -4M 46 000 -2M
investmentsInPropertyPlantAndEquipment -3M -4M -33M -3M -4M -5M
acquisitionsNet 0 -30M 0 0 -69M 0
purchasesOfInvestments 0 -16M 0 0 25M -21M
salesMaturitiesOfInvestments 0 16M 17M 31M 11M 23M
otherInvestingActivites 0 46M 0 0 44M 0
netCashUsedForInvestingActivites -3M 12M -16M 29M 7M -3M
debtRepayment -261 000 -248 000 -243 000 -240 000 -237 000 -225 000
commonStockIssued 3M 815 000 0 0 0 0
commonStockRepurchased -84 000 -435 000 -299 000 -6M -65 000 -563 000
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 2M 815 000 4M 462 000 2M 383 000
netCashUsedProvidedByFinancingActivities 2M 132 000 3M -6M 2M -405 000
effectOfForexChangesOnCash 109 000 -166 000 -26 000 25 000 246 000 -305 000
netChangeInCash 4M 13M -10M 19M 9M -6M
cashAtEndOfPeriod 84M 81M 67M 77M 58M 49M
cashAtBeginningOfPeriod 81M 67M 77M 58M 49M 55M
operatingCashFlow 4M 2M 3M -4M 46 000 -2M
capitalExpenditure -3M -4M -33M -3M -4M -5M
freeCashFlow 1M -2M -30M -7M -4M -7M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-07-25 ET (fiscal 2023 q2)
2023 q1
2023-05-02 ET (fiscal 2023 q1)
2022 q4
2023-02-21 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-15 21:01 ET
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
2024-01-25 13:00 ET
AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference
2024-01-08 13:00 ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024
2024-01-04 13:00 ET
AtriCure Appoints Shlomi Nachman to the Board of Directors
2023-12-20 13:00 ET
AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-15 13:00 ET
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference
2023-11-14 13:00 ET
AtriCure Releases 2023 ESG Report
2023-11-01 20:01 ET
AtriCure Reports Third Quarter 2023 Financial Results
2023-10-31 12:00 ET
AtriCure to Participate in the Stifel 2023 Healthcare Conference
2023-10-11 12:00 ET
AtriCure to Announce Third Quarter 2023 Financial Results
2023-07-25 20:01 ET
AtriCure Reports Second Quarter 2023 Financial Results
2023-07-21 12:00 ET
AtriCure to Participate at Upcoming Investor Conferences
2023-07-03 12:00 ET
AtriCure to Announce Second Quarter 2023 Financial Results
2023-05-02 20:01 ET
AtriCure Reports First Quarter 2023 Financial Results
2023-04-19 12:00 ET
AtriCure to Participate in the 2023 Bank of America Health Care Conference and Host a Cryo Nerve Block Therapy Investor Education Webcast
2023-04-11 12:00 ET
AtriCure to Announce First Quarter 2023 Financial Results
2023-04-03 12:00 ET
AtriCure to Participate in the 22nd Annual Needham Virtual Healthcare Conference
2023-02-21 21:00 ET
AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
2023-02-17 13:00 ET
AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference
2023-01-31 13:00 ET
AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial
2023-01-24 13:00 ET
AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference
2023-01-09 13:00 ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023
2022-12-20 13:00 ET
AtriCure to Participate in the 41st Annual J.P. Morgan Healthcare Conference
2022-12-08 15:30 ET
AtriCure Wins 2022 NACD Diversity, Equity, & Inclusion Award
2022-11-08 13:00 ET
AtriCure to Present at 34th Annual Piper Sandler Healthcare Conference
2022-11-01 20:01 ET
AtriCure Reports Third Quarter 2022 Financial Results
2022-10-25 12:00 ET
AtriCure to Participate in Upcoming Investor Conferences
2022-10-11 12:00 ET
AtriCure to Announce Third Quarter 2022 Financial Results
2022-09-06 12:00 ET
AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
2022-08-16 12:00 ET
AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-02 20:00 ET
AtriCure Reports Second Quarter 2022 Financial Results
2022-07-20 12:00 ET
AtriCure to Participate at Upcoming Investor Conferences
2022-07-12 12:00 ET
AtriCure to Announce Second Quarter 2022 Financial Results
2022-06-07 12:00 ET
AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial
2022-06-01 12:00 ET
AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer
2022-05-03 20:00 ET
AtriCure Reports First Quarter 2022 Financial Results
2022-04-12 12:00 ET
AtriCure Launches EnCompass® Clamp, a part of Isolator Synergy™ Ablation System
2022-04-11 12:00 ET
AtriCure to Announce First Quarter 2022 Financial Results
2022-02-15 21:01 ET
AtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results
2022-02-08 13:00 ET
AtriCure Publishes Inaugural ESG Report
2022-02-01 13:00 ET
AtriCure to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2022-01-25 13:00 ET
AtriCure to Announce Fourth Quarter and Full Year 2021 Financial Results
2022-01-10 12:00 ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022
2021-12-20 13:00 ET
AtriCure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
2021-11-12 13:00 ET
AtriCure to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference
2021-11-03 20:01 ET
AtriCure Reports Third Quarter 2021 Financial Results
2021-10-26 12:00 ET
AtriCure to Participate in Upcoming Investor Conferences
2021-10-05 12:00 ET
AtriCure to Announce Third Quarter 2021 Financial Results
2021-08-31 12:00 ET
AtriCure to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-04 20:01 ET
AtriCure Reports Second Quarter 2021 Financial Results
2021-07-30 12:00 ET
AtriCure to Participate at the Canaccord 41st Annual Growth Conference
2021-07-07 12:00 ET
AtriCure to Announce Second Quarter 2021 Financial Results
2021-06-15 11:00 ET
AtriCure Names Two New Members to the Board of Directors
2021-04-29 11:00 ET
AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
2021-04-27 20:01 ET
AtriCure Reports First Quarter 2021 Financial Results
2021-04-08 12:00 ET
AtriCure Names B. Kristine Johnson Board Chair
2021-04-06 12:00 ET
AtriCure to Announce First Quarter 2021 Financial Results
2021-03-02 21:01 ET
AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference
2021-02-23 21:01 ET
AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results
2021-02-10 13:00 ET
AtriCure to Participate at the SVB Leerink 10th Annual Global Healthcare Conference
2021-02-02 13:00 ET
AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results
2021-01-11 12:00 ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020
2021-01-04 13:00 ET
AtriCure Announces Labeling Expansion for Cryo Nerve Block Therapy
2020-12-14 13:00 ET
AtriCure to Participate in the 39th Annual J.P. Morgan Healthcare Conference
2020-11-19 13:00 ET
AtriCure to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-05 21:01 ET
AtriCure Reports Third Quarter 2020 Financial Results
2020-10-26 12:00 ET
AtriCure to Participate in Upcoming Investor Conferences
2020-10-13 12:00 ET
AtriCure to Announce Third Quarter 2020 Financial Results
2020-09-01 12:00 ET
AtriCure to Participate at the Morgan Stanley 18th Annual Global Healthcare Conference
2020-08-06 20:00 ET
AtriCure Announces Angie Wirick as Chief Financial Officer
2020-07-29 12:00 ET
AtriCure to Participate at Upcoming Investor Conferences
2020-07-28 20:01 ET
AtriCure Reports Second Quarter 2020 Financial Results
2020-07-07 12:00 ET
AtriCure to Announce Second Quarter 2020 Financial Results
2020-05-12 00:10 ET
AtriCure Announces Pricing of Public Offering of Common Stock
2020-05-11 11:16 ET
AtriCure Announces Proposed Public Offering of Common Stock
2020-05-08 12:47 ET
AtriCure Announces Results from CONVERGE IDE Clinical Trial
2020-04-30 12:30 ET
AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41st Annual Heart Rhythm Society (HRS) Virtual Meeting
2020-04-29 20:01 ET
AtriCure Reports First Quarter 2020 Financial Results
2020-04-27 20:02 ET
AtriCure to Participate at Upcoming Investor Conferences
2020-04-15 12:00 ET
AtriCure to Announce First Quarter 2020 Financial Results
2020-04-13 12:00 ET
AtriCure Announces CONVERGE IDE Trial Results Accepted for Late-Breaking Clinical Trial Sessions at Annual Heart Rhythm Society (HRS) Meeting
2020-04-09 12:00 ET
AtriCure Announces Preliminary Financial Results for First Quarter 2020 and Provides COVID-19 Pandemic Update
2020-02-18 21:01 ET
AtriCure Reports Fourth Quarter 2019 and Full Year 2019 Financial Results
2020-02-03 13:00 ET
AtriCure to Participate at the SVB Leerink 9th Annual Global Healthcare Conference
2020-01-28 13:00 ET
AtriCure to Announce Fourth Quarter and Full Year 2019 Financial Results
2020-01-13 13:00 ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2019, Provides Financial Outlook for 2020
2020-01-07 13:00 ET
AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol
2019-12-16 13:00 ET
AtriCure to Participate at the 38th Annual JP Morgan Healthcare Conference
2019-12-04 13:00 ET
AtriCure Names Two Industry Veterans to Board of Directors
2019-11-12 13:00 ET
AtriCure to Participate at the Piper Jaffray 31st Annual Healthcare Conference
2019-10-30 20:02 ET
AtriCure Reports Third Quarter 2019 Financial Results
2019-10-21 12:00 ET
AtriCure to Participate in Upcoming Investor Conferences
2019-10-08 12:00 ET
AtriCure to Announce Third Quarter 2019 Financial Results

SEC forms

Show financial reports only

SEC form 10
2024-02-16 00:00 ET
AtriCure published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
AtriCure published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
AtriCure reported for 2023 q4
SEC form 10
2023-11-02 12:17 ET
AtriCure published news for 2023 q3
SEC form 10
2023-11-02 00:00 ET
AtriCure published news for 2023 q3
SEC form 8
2023-11-01 16:01 ET
AtriCure reported for 2023 q3
SEC form 10
2023-07-26 13:42 ET
AtriCure published news for 2023 q2
SEC form 10
2023-07-26 00:00 ET
AtriCure published news for 2023 q2
SEC form 6
2023-07-25 16:00 ET
AtriCure reported for 2023 q2
SEC form 8
2023-07-25 00:00 ET
AtriCure published news for 2023 q2
SEC form 6
2023-05-26 11:51 ET
AtriCure published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
AtriCure published news for 2023 q1
SEC form 8
2023-05-02 00:00 ET
AtriCure published news for 2023 q1
SEC form 10
2023-02-22 00:00 ET
AtriCure reported for 2022 q4
SEC form 8
2023-02-21 00:00 ET
AtriCure reported for 2022 q4
SEC form 8
2023-01-09 00:00 ET
AtriCure published news for 2022 q4
SEC form 10
2022-11-02 00:00 ET
AtriCure reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
AtriCure reported for 2022 q3
SEC form 10
2022-08-03 00:00 ET
AtriCure reported for 2022 q2
SEC form 8
2022-08-02 00:00 ET
AtriCure reported for 2022 q2
SEC form 10
2022-05-04 00:00 ET
AtriCure reported for 2022 q1
SEC form 8
2022-05-03 00:00 ET
AtriCure reported for 2022 q1
SEC form 10
2022-02-17 00:00 ET
AtriCure published news for 2021 q4
SEC form 8
2022-02-15 00:00 ET
AtriCure published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
AtriCure published news for 2021 q4
SEC form 10
2021-11-04 00:00 ET
AtriCure published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
AtriCure published news for 2021 q3
SEC form 10
2021-08-05 00:00 ET
AtriCure published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
AtriCure published news for 2021 q2
SEC form 10
2021-04-28 00:00 ET
AtriCure published news for 2021 q1
SEC form 8
2021-04-27 00:00 ET
AtriCure published news for 2021 q1